louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04149041: The Applications of Point-of-care Ultrasound in ED Unselected, Non-critical Patients
Official title: The Applications of Point-of-care Ultrasound in ED Unselected, Non-critical Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ultrasound Therapy; Complications
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2019-11-04
Enrollment: 10000
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From June 2014 to August 2019, adult patients in the emergency department receiving ultrasound were enrolled.

Brief summary: to investigate prevalence of agreement between sonographic and clinical diagnosis in adult patients seen in an emergency department.

Detailed description: Point-of-care ultrasound (POCUS) can improve patient management in the emergency department (ED). However, previous studies have focused only on selected groups of patients, such as trauma, shock, dyspnea, or critically ill patients, or patients with an already known diagnosis. Most patients seen in the ED do not match these criteria. This study aims to investigate prevalence of agreement between sonographic and clinical diagnosis in adult patients seen in an emergency department.

Eligibility criteria: Inclusion Criteria:

* adult patients in the emergency department receiving ultrasonographic examinations were enrolled.

Exclusion Criteria:

* adult patients in the emergency department not receiving ultrasonographic examinations.

Primary outcomes:
measure: number of agreement between the sonographic diagnosis and the clinical diagnosis
timeFrame: one month
measure: length of stay at the emergency department
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: National Taiwan University Hospital
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wang PH, Chen JY, Ling DA, Lee AF, Ko YC, Lien WC, Huang CH. Earlier point-of-care ultrasound, shorter length of stay in patients with acute flank pain. Scand J Trauma Resusc Emerg Med. 2022 Apr 21;30(1):29. doi: 10.1186/s13049-022-01017-1.
Clinical trial NCT01716741: Identification of Undiagnosed Gaucher Disease
Official title: Identification of Undiagnosed Gaucher Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gaucher Disease
Keywords: Gaucher disease
lysosomal storage disorder
metabolic disease
medical records review
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: Genzyme, a Sanofi Company
First posted: 2012-10-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Partners HealthCare maintains a Patient Data Registry (PDR) with information from all patient encounters at Partners HealthCare facilities. We intend to utilize the PDR to identify groups of patient who are of high clinical suspicion for undiagnosed Gaucher disease. A group of potential participants will be identified through the PDR. Detailed records will be requested to further narrow to ideal participants based upon previously existing diagnoses and symptoms. Participants will be invited to partake in the study via a letter from their Partners care provider with supporting study details. Study participants will be evaluated in a one-time visit. A complete family and medical history will be collected. A physical exam will be performed, and up to 20cc of blood will be drawn. All participants will be notified of their disease status via letter and phone call from the study staff. If the study participant is diagnosed with GD through this evaluation, proper follow-up recommendations and referrals will be provided. Our intent is to determine if existing patient data can successfully be utilized to aid in the identification of patients with rare genetic disease.


Eligibility criteria: Inclusion Criteria:

* Must have records available in the Partners HealthCare Patient Data Registry

Exclusion Criteria:

* Must not have a diagnosis of Gaucher disease

Primary outcomes:
measure: number of patients with previously undiagnosed GD identified
timeFrame: up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hosptial
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Michael F Murray, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04008641: Pertinence of Pediatric Message Delivered to Parents During Antenatal Consultations
Official title: Pertinence of Pediatric Message Delivered to Parents During Antenatal Consultations
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Information Understanding and Psychological Impact
Keywords: pediatric consultation
psychological
comprehension
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2019-07-05
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All parents with need antenatal pediatric urgently or usual consultation

Brief summary: Antenatal consultations are experienced as traumatic for many couples. Moreover, when informations are given urgently ; comprehension and psychological impact aren't well evaluate.

This project aims to evaluate comprehension and psychological impact, for both members of the couple, when informations are provided urgently or during usual consultations.


Eligibility criteria: Inclusion Criteria:

* Parents whom pregnancies need antenatal pediatric consultation
* Non opposition

Exclusion Criteria:

* \< 18 years old
* Psychiatric illness

Primary outcomes:
measure: Comprehension and psychological impact ; urgently informations compared with usual consultations
timeFrame: At pregnancy follow-up visit up to 36 weeks gestation
Secondary outcomes:
measure: Difference between both members of the couple
timeFrame: At pregnancy follow-up visit up to 36 weeks gestation
measure: Comprehension and psychological impact, at pregnancy's theoric term compared with first survey Same scale
timeFrame: At delivery at 41 weeks gestation
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHRU Nancy - Maternité Régionale
Study officials:
affiliation: CHRU NANCY - Maternité Régionale
name: Jean-Michel HASCOET, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06056141: Induction of Labour at Term With Low Dose Oral Misoprostol Versus a Foley Catheter
Official title: Induction of Labour at Term With Low Dose Oral Misoprostol Versus a Foley Catheter: a Multicentre Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Induction of Labor
Keywords: Induction of labor
low dose misoprostol
Foley Catheter
Lead sponsor: Kazakhstan's Medical University "KSPH"
Sponsor class: OTHER
Collaborators: name: Asfendiyarov Kazakh National Medical University
First posted: 2023-09-28
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: multicentre randomised controlled trial
Primary purpose: TREATMENT

Brief summary: Comparison of efficacy and safety of low-dose oral Misoprostol versus folley catheter for preinduction in women with an immature cervix at term.

Detailed description: Open-label randomised trial in 2 hospitals in the Almaty,Kazakhstan. Women with a term singleton pregnancy in cephalic presentation, an unfavourable cervix, intact membranes, and without a previous caesarean section will be randomly allocated to 2 groups: 1 group -cervical ripening with 25 μg oral misoprostol once every 2 hour, 2 nd group- a 30 mL transcervical Foley catheter. The primary outcome will be vaginal delivery within 24 hours(to evaluate effectiveness) and secondary outcoms 1-5-min Apgar score and hospitalization in ICU, hyperstimulation frequency and hemorrage (for evaluating safety)

Eligibility criteria: Inclusion Criteria:

* women with an unfavourable cervix who will scheduled for induction of labour

Exclusion Criteria:

* Women with previous caesarean sections unable to give informed consent Multiple pregnancy History of allergy to misoprostol Ruptured membranes Chorioamnionitis All cases when physiological childbirth is impossible (placenta previa,transverse position of the fetus )

Primary outcomes:
measure: Efficiency of induction
timeFrame: 24 hours.
Secondary outcomes:
measure: Safety for baby
timeFrame: 5 min
measure: Safety for mother
timeFrame: during the labour induction
Other outcomes:
Locations:
city: Almaty
country: Kazakhstan
facility: City Perinatology Centre 3
city: Almaty
country: Kazakhstan
facility: Center for Perinatology and Pediatric Cardiac Surgery
Study officials:
References:
Clinical trial NCT00913341: To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg
Official title: Bioavailability of Alprazolam Tablets
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Anxiety
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-06-04
Enrollment: 30
Sex: MALE
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence based on AUC and Cmax
timeFrame: 13 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: PharmaKinetics Laboratories Inc.
name: Niloufar Guiv, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02858141: Onco-geriatric Database of Patients With Pancreatic Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pancreatic Neoplasms
Keywords: oncogeriatric evaluation
pancreatic cancer
Database
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2016-08-08
Enrollment: 300
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elderly patients with pancreatic cancer who underwent an oncogeriatric evaluation

Brief summary: This data base has been set in order to gather oncogeriatric information from elderly patients with pancreatic cancer who underwent an oncogeriatric evaluation.

ONCOGEPAN database gathers data from deux institutions (Institut Paoli-Calmettes and Assistance Publique des Hôpitaux de Marseille) involved in Marseille SIRIC (Integrated Cancer Research Site).


Eligibility criteria: Inclusion Criteria:

* Age\>70 years
* Oncogeriatric evaluation done

Exclusion Criteria:

* Patient refusal to participate in the study

Primary outcomes:
measure: Collection of oncogeriatric data for future research studies
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli Calmettes
state: Bouches du Rhône
city: Marseille
country: France
facility: Assistance Publique des Hôpitaux de Marseille
state: Bouches du Rhône
Study officials:
affiliation: Assistance Publique des Hôpitaux de Marseille
name: Elodie Crétel
role: PRINCIPAL_INVESTIGATOR
affiliation: Institut Paoli-Calmettes
name: Frédérique Rousseau
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06895941: Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
Official title: Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Lung Cancer (NSCLC)
Neoadjuvant Immunotherapy
Lead sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Sponsor class: OTHER
First posted: 2025-03-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Non-small cell lung cancer patients receiving neoadjuvant immunotherapy

Brief summary: The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.


Eligibility criteria: Inclusion Criteria:(1) aged 18 years or older; (2) pathological diagnosis of non-small cell lung cancer; (3) lesions resectable by surgery; (4) no EGFR mutation or ALK mutation; (5) eligible for indications of neoadjuvant immunotherapy for lung cancer.

-

Exclusion Criteria:(1) patients who had used any other antitumor drugs or radiotherapy; (2) comorbidities with other malignant neoplastic diseases or severe cardiovascular diseases; (3) uncontrollable diabetes mellitus or fasting blood glucose level higher than 11 mmol/L on the test day; (4) pregnancy or recent pregnancy plan; (5) distant metastasis.

-

Primary outcomes:
measure: FAPI PET/CT predicts efficacy
timeFrame: 2025.3.1-2027.3.1
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai East Hospital
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Pulmonary Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT02890641: Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Refractory Focal Epilepsy
Focal Cortical Dysplasia
Hemimegalencephaly
Tuberous Sclerosis
Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia in Epilepsy (MOGHE)
Keywords: Refratory Focal Epilepsy
Focal Cortical Dysplasia
Cortical Malformation
Hemimegalencephaly
Tuberous sclerosis
Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE)
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-09-07
Enrollment: 450
Sex: ALL
Minimum age (years): 3
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with focal drug-resistant epilepsy undergoing epilepsy surgery and their parents

Brief summary: Brain somatic mutations in genes belonging to the mTOR signaling pathway are a frequent cause of cortical malformations, including focal cortical dysplasia or hemimegalencephaly.

The present study aims to search for brain somatic mutations in paired blood-brain samples and perform functional validation in children with drug-resistant focal epilepsy


Eligibility criteria: Inclusion Criteria:

* Children with focal drug-resistant epilepsy including Focal Cortical Dysplasia, Hemimegalencephaly, Tuberous Sclerosis, Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), Hypothalamic Hamartomas, Sturge-Weber syndrome, Rasmussen encephalitis, gliomas)
* Their parents who have signed informed consent 1) for their child's participation (for parents) and 2) for themselves
* Social security coverage or foreign regime recognized in France

Exclusion Criteria:

* refusal to participate in the study
* contraindication to anaesthesia, to MRI or to surgery
* no medical insurance coverage

Primary outcomes:
measure: qualitative genetic analysis
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique Adolphe de Rothschld
Study officials:
affiliation: Fondation A de Rothschild
name: Mathilde CHIPAUX, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Institut du Cerveau et de la Moelle Epinière
name: Stephanie Boulac, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05139641: Multidisciplinary Shared Decision Making of Fertility Preservation in Young Women With Breast Cancer
Official title: Multidisciplinary Shared Decision Making of Fertility Preservation in Young Women With Breast Cancer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Young Womenwith Breast Cancer
Lead sponsor: MedicalExcellence
Sponsor class: OTHER
Collaborators: name: Asan Medical Center
First posted: 2021-12-01
Enrollment: 4100
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Multidisciplinary shared decision making of fertility preservation in Young womenwith Breast Cancer (MYBC): A Pragmatic stepped wedge cluster randomised trial


Eligibility criteria: Inclusion Criteria:

* Women aged 19 to 40 years old
* A person diagnosed with breast cancer by biopsy
* Those who don't have evidence of distant metastasis
* Eastern Cooperative Oncology Group(ECOG) performance status: 0-2 score
* Before registering for clinical trials, chemotherapy, radiation therapy, anti-hormone therapy, immunotherapy, and surgery are not performed
* A person who has fully understood and listened to the explanation of this clinical trial and then gave written consent

Exclusion Criteria:

* Histologically, a person diagnosed with follicular or sarcoma
* Those with a history of breast cancer (including recurrent breast cancer)
* A person diagnosed with another cancer before breast cancer
* A person diagnosed with metastatic breast cancer
* A person who has a mental illness and has a hard time understanding clinical trials
* Those who plan to conduct follow-up observation elsewhere(to change of hometowm)
* Menopausal factors without menstruation after more than a year from the last menstrual date
* A pregnant woman
* Inappropriate for participation in clinical trials

Primary outcomes:
measure: selection ratio of fertility preservation procedure
timeFrame: selection ratio of fertility preservation procedure from Baseline to six years
Secondary outcomes:
measure: The success rate of pregnancy
timeFrame: The success rate of pregnancy from Baseline to six years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Medical Excellence
Study officials:
References:
Clinical trial NCT01706341: The Effect of Administering a Small Dose of Glucose During Cesarean Section
Official title: The Effect of Administering a Small Dose of Glucose on the Pregnant Women and Their Neonates During Cesarean Section
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cesarean Section
Keywords: cesarean section
intravenous fluid
a glucose-containing solution
fetal hypoglycemia
neonatal hypoglycemia
Lead sponsor: Nagoya City University
Sponsor class: OTHER
First posted: 2012-10-15
Enrollment: 40
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effect of administering a small dose of glucose on the pregnant women and their neonates during cesarean section. We investigate the safety and efficacy of use of a glucose-containing solution for the pregnant women and the neonates.

Detailed description: Rapid infusion of large amount of glucose is associated with fetal hyperglycemia, hyperinsulinemia, and neonatal hypoglycemia. However, the effect of small dose of glucose is unclear. We conducted a pilot study of small dose of glucose. We investigated the effect of a glucose-containing fluid on the blood sugar of the umbilical artery. We found that in the case of no-glucose-containing fluid, there were some cases in which umbilical arterial concentration of glucose was less than 50 mg/dl, which might cause neonatal hypoglycemia. In addition, in the case of 1%-glucose-containing fluid, mean umbilical arterial concentration of glucose was 97 mg/dl.

The purpose of this study is to investigate the effect of administering a small dose of glucose on the pregnant women and their neonates during cesarean section. We investigate the safety and efficacy of use of a glucose-containing solution for the pregnant women and the neonates.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing cesarean section who met the criteria of the American Society of Anesthesiologists physical status of 1-2

Exclusion Criteria:

* ASA physical status \>=3, Obesity (BMI\>35), Height\>=175cm, Weight\>=80Kg

Primary outcomes:
measure: The blood glucose concentration in the neonates at one hour of age
timeFrame: One hour of age
Secondary outcomes:
measure: The blood glucose concentration in the neonates at two hour of age
timeFrame: Two hour of age
Other outcomes:
measure: Evidence of clinical complications (especially, low glucose symptoms)
timeFrame: Within the first 3 days after cesarean section
Locations:
city: Nagoya
country: Japan
facility: Departiment of Anesthesiology, Nagoya City University Hospital
Study officials:
affiliation: Department of Anesthesiology, Nagoya City Universtiy
name: Yoshihito Fujita, MD. PhD.
role: STUDY_CHAIR
References: